Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 261Neoplasms 143Breast Neoplasms 140Colorectal Neoplasms 124Prostatic Neoplasms 94Neoplasm Metastasis 93Multiple Myeloma 92Ovarian Neoplasms 91Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 62Recurrence 59Endometrial Neoplasms 55Melanoma 52Small Cell Lung Carcinoma 51Leukemia, Lymphocytic, Chronic, B-Cell 48Stomach Neoplasms 47Carcinoma, Renal Cell 46Leukemia, Myeloid, Acute 44Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Urinary Bladder Neoplasms 37Triple Negative Breast Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 36Lymphoma, Large B-Cell, Diffuse 36Head and Neck Neoplasms 36Carcinoma, Hepatocellular 35Lymphoma, Follicular 30Esophageal Neoplasms 30Myasthenia Gravis 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Neoplasms × 30 days × Clear all
NCT07038343 2026-05-13

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
480 enrolled
GastrointestinalHead & NeckThoracic

Biliary Tract Neoplasms, Carcinoma, Lung Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡